| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eicosanoids | 15 | 2023 | 284 | 4.890 |
Why?
|
| Epoxide Hydrolases | 13 | 2024 | 122 | 3.290 |
Why?
|
| Signal Processing, Computer-Assisted | 4 | 2018 | 1489 | 1.320 |
Why?
|
| Neoplasms | 22 | 2024 | 22371 | 1.250 |
Why?
|
| Inflammation | 16 | 2024 | 10873 | 1.080 |
Why?
|
| Neoplasms, Experimental | 6 | 2019 | 1230 | 1.060 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 4913 | 0.970 |
Why?
|
| Neovascularization, Pathologic | 18 | 2023 | 2631 | 0.950 |
Why?
|
| Docosahexaenoic Acids | 5 | 2019 | 914 | 0.950 |
Why?
|
| Cyclooxygenase 2 | 5 | 2023 | 598 | 0.930 |
Why?
|
| Prostaglandins | 3 | 2023 | 398 | 0.880 |
Why?
|
| Electrocardiography | 4 | 2018 | 6412 | 0.860 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 2 | 2023 | 44 | 0.820 |
Why?
|
| Antineoplastic Agents | 12 | 2021 | 13677 | 0.800 |
Why?
|
| Liver Regeneration | 2 | 2014 | 214 | 0.790 |
Why?
|
| Cytokines | 9 | 2021 | 7452 | 0.780 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 4 | 2023 | 319 | 0.770 |
Why?
|
| Lipid Metabolism | 4 | 2018 | 1904 | 0.710 |
Why?
|
| Macrophages | 9 | 2022 | 5802 | 0.660 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 3 | 2017 | 64 | 0.650 |
Why?
|
| Fatty Acids | 2 | 2024 | 1812 | 0.640 |
Why?
|
| Ketorolac | 1 | 2019 | 95 | 0.620 |
Why?
|
| Epoxy Compounds | 3 | 2013 | 137 | 0.620 |
Why?
|
| Thromboxane A2 | 1 | 2018 | 87 | 0.610 |
Why?
|
| Fatty Acids, Unsaturated | 4 | 2019 | 542 | 0.600 |
Why?
|
| Neovascularization, Physiologic | 3 | 2014 | 1370 | 0.540 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2011 | 423 | 0.540 |
Why?
|
| Osteopontin | 1 | 2018 | 311 | 0.530 |
Why?
|
| PPAR alpha | 2 | 2008 | 177 | 0.520 |
Why?
|
| Angiogenesis Inhibitors | 10 | 2011 | 2057 | 0.470 |
Why?
|
| Cardiotonic Agents | 1 | 2017 | 543 | 0.460 |
Why?
|
| Neuropilin-1 | 1 | 2014 | 91 | 0.450 |
Why?
|
| Lipids | 3 | 2023 | 3345 | 0.450 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 2014 | 93 | 0.450 |
Why?
|
| Tumor Microenvironment | 6 | 2024 | 3948 | 0.440 |
Why?
|
| Animals | 53 | 2024 | 169285 | 0.430 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 1561 | 0.430 |
Why?
|
| Fluorouracil | 1 | 2018 | 1652 | 0.420 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2014 | 1399 | 0.410 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3115 | 0.400 |
Why?
|
| Wound Healing | 2 | 2014 | 2815 | 0.400 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3238 | 0.400 |
Why?
|
| Mice | 39 | 2024 | 82049 | 0.400 |
Why?
|
| Algorithms | 3 | 2018 | 14164 | 0.400 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 2271 | 0.390 |
Why?
|
| Aflatoxin B1 | 2 | 2022 | 17 | 0.390 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 2029 | 0.380 |
Why?
|
| Ovarian Neoplasms | 2 | 2019 | 4916 | 0.380 |
Why?
|
| Epidermis | 1 | 2014 | 539 | 0.370 |
Why?
|
| Inflammation Mediators | 4 | 2023 | 1892 | 0.370 |
Why?
|
| Databases as Topic | 3 | 2018 | 472 | 0.370 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1810 | 0.360 |
Why?
|
| Carcinoma, Lewis Lung | 5 | 2013 | 108 | 0.350 |
Why?
|
| Preoperative Care | 1 | 2019 | 2258 | 0.340 |
Why?
|
| Hep G2 Cells | 2 | 2021 | 378 | 0.340 |
Why?
|
| Keratinocytes | 1 | 2014 | 876 | 0.330 |
Why?
|
| Phagocytosis | 3 | 2021 | 1530 | 0.330 |
Why?
|
| Colonic Neoplasms | 2 | 2018 | 2541 | 0.330 |
Why?
|
| Bone Remodeling | 1 | 2013 | 583 | 0.330 |
Why?
|
| Fetus | 1 | 2017 | 1883 | 0.330 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2016 | 2258 | 0.320 |
Why?
|
| Arachidonic Acid | 7 | 2023 | 429 | 0.320 |
Why?
|
| Glioblastoma | 2 | 2022 | 3464 | 0.310 |
Why?
|
| Glioma | 2 | 2022 | 3503 | 0.310 |
Why?
|
| Melanoma, Experimental | 4 | 2017 | 559 | 0.310 |
Why?
|
| Cell Proliferation | 9 | 2022 | 10478 | 0.310 |
Why?
|
| Carcinogens | 2 | 2020 | 453 | 0.300 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 1798 | 0.300 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4363 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 2846 | 0.290 |
Why?
|
| Pediatrics | 2 | 2020 | 3629 | 0.290 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3072 | 0.290 |
Why?
|
| Fenofibrate | 1 | 2008 | 87 | 0.290 |
Why?
|
| Blood Platelets | 1 | 2018 | 2479 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 17 | 2021 | 22380 | 0.280 |
Why?
|
| Signal Transduction | 10 | 2022 | 23648 | 0.280 |
Why?
|
| Aspirin | 1 | 2019 | 3135 | 0.280 |
Why?
|
| Atherosclerosis | 1 | 2023 | 3433 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2830 | 0.270 |
Why?
|
| Cell Line, Tumor | 8 | 2022 | 17142 | 0.270 |
Why?
|
| Endothelial Cells | 5 | 2014 | 3589 | 0.270 |
Why?
|
| Humans | 56 | 2024 | 768171 | 0.260 |
Why?
|
| Thiazoles | 2 | 2003 | 1542 | 0.250 |
Why?
|
| MicroRNAs | 1 | 2021 | 3803 | 0.250 |
Why?
|
| Granulocytes | 1 | 2007 | 551 | 0.240 |
Why?
|
| Regeneration | 1 | 2013 | 1524 | 0.230 |
Why?
|
| Heart Rate | 1 | 2015 | 4214 | 0.230 |
Why?
|
| Cell Movement | 3 | 2015 | 5213 | 0.220 |
Why?
|
| Mice, Transgenic | 5 | 2017 | 9561 | 0.200 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 9118 | 0.200 |
Why?
|
| PPAR gamma | 1 | 2005 | 487 | 0.200 |
Why?
|
| Pain | 1 | 2017 | 5099 | 0.200 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2014 | 246 | 0.190 |
Why?
|
| Liver | 2 | 2014 | 7578 | 0.190 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 10266 | 0.190 |
Why?
|
| Cell Death | 3 | 2022 | 1680 | 0.190 |
Why?
|
| Mice, Knockout | 5 | 2019 | 14488 | 0.190 |
Why?
|
| Hypertension | 2 | 2020 | 8616 | 0.180 |
Why?
|
| Fibroblast Growth Factor 2 | 4 | 2008 | 594 | 0.180 |
Why?
|
| Neoplastic Processes | 1 | 2020 | 36 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9419 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 3612 | 0.180 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 2517 | 0.170 |
Why?
|
| Stem Cells | 1 | 2013 | 3538 | 0.170 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 3604 | 0.170 |
Why?
|
| Plasminogen Inactivators | 1 | 2019 | 37 | 0.160 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 461 | 0.160 |
Why?
|
| Biology | 1 | 2021 | 292 | 0.160 |
Why?
|
| Sesquiterpenes | 5 | 2010 | 176 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2014 | 3517 | 0.150 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 333 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 2334 | 0.150 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 18349 | 0.150 |
Why?
|
| Mice, SCID | 4 | 2019 | 2627 | 0.150 |
Why?
|
| Neuroblastoma | 2 | 2020 | 1266 | 0.150 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 859 | 0.150 |
Why?
|
| Disease Progression | 4 | 2020 | 13668 | 0.150 |
Why?
|
| Platinum | 1 | 2019 | 222 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 2020 | 665 | 0.140 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2014 | 319 | 0.140 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 531 | 0.140 |
Why?
|
| Cyclooxygenase 1 | 1 | 2017 | 98 | 0.140 |
Why?
|
| Fuzzy Logic | 1 | 2017 | 58 | 0.140 |
Why?
|
| Pandemics | 3 | 2022 | 8747 | 0.130 |
Why?
|
| Phosphatidylserines | 1 | 2017 | 186 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2019 | 605 | 0.130 |
Why?
|
| Lipoxins | 1 | 2019 | 419 | 0.130 |
Why?
|
| Cyclohexanes | 5 | 2010 | 152 | 0.130 |
Why?
|
| Receptor, TIE-2 | 2 | 2014 | 183 | 0.130 |
Why?
|
| Normal Distribution | 1 | 2016 | 272 | 0.130 |
Why?
|
| Lipoxygenases | 2 | 2014 | 13 | 0.130 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2016 | 133 | 0.120 |
Why?
|
| Taxoids | 1 | 2019 | 667 | 0.120 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2017 | 254 | 0.120 |
Why?
|
| Chemokines | 1 | 2019 | 963 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 646 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2022 | 1351 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3620 | 0.110 |
Why?
|
| Ischemia | 1 | 2023 | 1900 | 0.110 |
Why?
|
| Apoptosis | 3 | 2020 | 9527 | 0.110 |
Why?
|
| Tumor Burden | 2 | 2017 | 1906 | 0.110 |
Why?
|
| Vasoconstriction | 1 | 2016 | 592 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 1074 | 0.110 |
Why?
|
| Reperfusion Injury | 1 | 2020 | 1039 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 6124 | 0.110 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2014 | 1057 | 0.110 |
Why?
|
| Organotechnetium Compounds | 1 | 2013 | 133 | 0.110 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 3056 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2014 | 225 | 0.100 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2013 | 103 | 0.100 |
Why?
|
| Medicine | 1 | 2021 | 945 | 0.100 |
Why?
|
| Blotting, Northern | 1 | 2014 | 1553 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 11095 | 0.100 |
Why?
|
| Endothelium, Vascular | 5 | 2012 | 4428 | 0.100 |
Why?
|
| Receptors, Eicosanoid | 1 | 2011 | 12 | 0.100 |
Why?
|
| Piperidines | 1 | 2020 | 1667 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 1793 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2012 | 178 | 0.090 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2022 | 1930 | 0.090 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 928 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2017 | 1573 | 0.090 |
Why?
|
| Epithelium | 1 | 2016 | 1607 | 0.090 |
Why?
|
| Cell Line | 4 | 2020 | 15602 | 0.090 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 391 | 0.090 |
Why?
|
| Retinal Neovascularization | 1 | 2014 | 288 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 983 | 0.090 |
Why?
|
| Mouth Neoplasms | 1 | 2016 | 597 | 0.090 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 1904 | 0.090 |
Why?
|
| Colon | 1 | 2018 | 1801 | 0.090 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2010 | 225 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 6231 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 3728 | 0.080 |
Why?
|
| Anticarcinogenic Agents | 1 | 2011 | 251 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2014 | 5028 | 0.080 |
Why?
|
| Colitis | 1 | 2018 | 1242 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2022 | 2029 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 996 | 0.080 |
Why?
|
| Metabolomics | 1 | 2019 | 1674 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2017 | 2766 | 0.080 |
Why?
|
| Eye | 1 | 2013 | 712 | 0.080 |
Why?
|
| Artifacts | 1 | 2018 | 1926 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 2152 | 0.080 |
Why?
|
| Male | 20 | 2021 | 364731 | 0.080 |
Why?
|
| Ligands | 2 | 2008 | 3284 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 384 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 8052 | 0.070 |
Why?
|
| Fish Oils | 1 | 2011 | 483 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 1907 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1942 | 0.070 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2013 | 1140 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2024 | 4754 | 0.070 |
Why?
|
| Collagen | 3 | 2013 | 2645 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2016 | 1946 | 0.070 |
Why?
|
| Sucrose | 1 | 2008 | 157 | 0.070 |
Why?
|
| Radiation Chimera | 1 | 2007 | 216 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 1197 | 0.070 |
Why?
|
| Polymers | 1 | 2014 | 1630 | 0.070 |
Why?
|
| Cattle | 5 | 2008 | 3819 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2019 | 4413 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2010 | 800 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2015 | 2059 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 866 | 0.060 |
Why?
|
| RNA Interference | 1 | 2014 | 2832 | 0.060 |
Why?
|
| Pyrroles | 1 | 2011 | 1124 | 0.060 |
Why?
|
| Thrombospondin 1 | 1 | 2007 | 257 | 0.060 |
Why?
|
| Corneal Neovascularization | 1 | 2007 | 184 | 0.060 |
Why?
|
| Endothelium | 1 | 2008 | 768 | 0.060 |
Why?
|
| Base Sequence | 2 | 2014 | 12422 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3428 | 0.060 |
Why?
|
| Survival Rate | 2 | 2018 | 12840 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2020 | 8543 | 0.060 |
Why?
|
| Monocytes | 1 | 2014 | 2605 | 0.060 |
Why?
|
| Cell Division | 5 | 2008 | 4477 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 17623 | 0.060 |
Why?
|
| Cornea | 3 | 2008 | 1316 | 0.060 |
Why?
|
| Zebrafish | 1 | 2015 | 3035 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 5442 | 0.050 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2023 | 48 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1836 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 6512 | 0.050 |
Why?
|
| Macular Degeneration | 1 | 2010 | 1015 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 3409 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2002 | 12171 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2014 | 1986 | 0.050 |
Why?
|
| Leukotrienes | 1 | 2023 | 232 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2017 | 1760 | 0.050 |
Why?
|
| Endothelial Growth Factors | 2 | 2001 | 672 | 0.050 |
Why?
|
| Kidney | 2 | 2015 | 7064 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2002 | 211 | 0.050 |
Why?
|
| Child | 2 | 2020 | 80917 | 0.050 |
Why?
|
| Lymphokines | 2 | 2001 | 925 | 0.050 |
Why?
|
| Cytochalasins | 1 | 2000 | 19 | 0.050 |
Why?
|
| Female | 8 | 2019 | 397187 | 0.040 |
Why?
|
| Glomerular Mesangium | 1 | 2020 | 98 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2023 | 597 | 0.040 |
Why?
|
| Granuloma | 1 | 2022 | 329 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4058 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2004 | 717 | 0.040 |
Why?
|
| Diet | 2 | 2022 | 8089 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 2414 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2016 | 11677 | 0.040 |
Why?
|
| Sulindac | 1 | 1999 | 29 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2007 | 2709 | 0.040 |
Why?
|
| Lung | 2 | 2016 | 10101 | 0.040 |
Why?
|
| Enalapril | 1 | 2020 | 317 | 0.040 |
Why?
|
| Rats | 2 | 2011 | 23782 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 1778 | 0.040 |
Why?
|
| Triclosan | 1 | 2018 | 58 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 1999 | 225 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2000 | 2195 | 0.040 |
Why?
|
| Prognosis | 1 | 2018 | 30009 | 0.040 |
Why?
|
| RNA, Transfer | 1 | 1999 | 284 | 0.040 |
Why?
|
| Thalidomide | 2 | 2002 | 886 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 258 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 5717 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 2016 | 12801 | 0.030 |
Why?
|
| Immunity | 1 | 2022 | 1003 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2004 | 957 | 0.030 |
Why?
|
| Biological Transport | 2 | 2013 | 2085 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 5863 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 13586 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2017 | 412 | 0.030 |
Why?
|
| Superoxides | 1 | 2017 | 389 | 0.030 |
Why?
|
| Blood Gas Analysis | 1 | 2016 | 384 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 5704 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 30255 | 0.030 |
Why?
|
| Cytochromes | 1 | 2014 | 18 | 0.030 |
Why?
|
| Solubility | 1 | 2016 | 1086 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 10763 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 588 | 0.030 |
Why?
|
| Hemangioma | 1 | 1999 | 727 | 0.030 |
Why?
|
| Lipoxygenase | 1 | 2014 | 72 | 0.030 |
Why?
|
| Biotransformation | 1 | 2014 | 166 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2022 | 1469 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 1999 | 1197 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2015 | 321 | 0.030 |
Why?
|
| Penicillamine | 1 | 2013 | 60 | 0.030 |
Why?
|
| Intestines | 1 | 2022 | 1909 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1515 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2000 | 794 | 0.030 |
Why?
|
| Oxygen | 2 | 2016 | 4270 | 0.030 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2013 | 56 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2017 | 741 | 0.030 |
Why?
|
| Androgens | 1 | 2001 | 1281 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2013 | 3623 | 0.030 |
Why?
|
| Fibrosis | 1 | 2020 | 2081 | 0.030 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2015 | 355 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2017 | 1688 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 4585 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1999 | 1179 | 0.020 |
Why?
|
| Angiostatins | 2 | 2002 | 64 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 662 | 0.020 |
Why?
|
| Metabolome | 1 | 2018 | 1009 | 0.020 |
Why?
|
| Plasminogen | 2 | 2002 | 144 | 0.020 |
Why?
|
| Endostatins | 2 | 2002 | 167 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2002 | 3334 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2014 | 628 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2016 | 788 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 425 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2010 | 250 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2014 | 565 | 0.020 |
Why?
|
| Integrases | 1 | 2012 | 520 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4648 | 0.020 |
Why?
|
| Cell Count | 1 | 2013 | 1832 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2001 | 749 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 2222 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2010 | 1163 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2000 | 1084 | 0.020 |
Why?
|
| Kinetics | 2 | 2010 | 6330 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 1680 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 874 | 0.020 |
Why?
|
| Microscopy | 1 | 2013 | 909 | 0.020 |
Why?
|
| Descemet Membrane | 1 | 2008 | 70 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 2010 | 693 | 0.020 |
Why?
|
| Microvessels | 1 | 2011 | 585 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 4149 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2016 | 4194 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2014 | 2003 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 2885 | 0.020 |
Why?
|
| Microcirculation | 1 | 2010 | 1281 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 1339 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3740 | 0.020 |
Why?
|
| Capillaries | 1 | 2008 | 755 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 1942 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 3772 | 0.010 |
Why?
|
| Centrosome | 1 | 2004 | 210 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 2062 | 0.010 |
Why?
|
| Models, Biological | 1 | 1999 | 9497 | 0.010 |
Why?
|
| Karyotyping | 1 | 2004 | 1177 | 0.010 |
Why?
|
| Phenylbutyrates | 1 | 2002 | 72 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2008 | 1162 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 7609 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2004 | 573 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 4355 | 0.010 |
Why?
|
| Mycotoxins | 1 | 2000 | 35 | 0.010 |
Why?
|
| Aspergillus | 1 | 2000 | 95 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 2828 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 725 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 13091 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1999 | 305 | 0.010 |
Why?
|
| Aminopeptidases | 1 | 2000 | 114 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 411 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 13422 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2000 | 386 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2004 | 1337 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 2521 | 0.010 |
Why?
|
| Peptide Fragments | 2 | 2002 | 5151 | 0.010 |
Why?
|
| Mitochondria | 1 | 2011 | 3683 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 521 | 0.010 |
Why?
|
| Protein Binding | 1 | 2010 | 9343 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2001 | 11101 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2000 | 719 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 11930 | 0.010 |
Why?
|
| Biphenyl Compounds | 1 | 2002 | 1026 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8648 | 0.010 |
Why?
|
| Platelet Count | 1 | 1999 | 787 | 0.010 |
Why?
|
| Time Factors | 2 | 2011 | 40220 | 0.010 |
Why?
|
| Syndrome | 1 | 1999 | 3273 | 0.010 |
Why?
|
| Body Composition | 1 | 2002 | 2462 | 0.010 |
Why?
|
| Rabbits | 1 | 1999 | 4773 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 19025 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 4627 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2002 | 2907 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1999 | 4034 | 0.010 |
Why?
|
| Brain | 1 | 2013 | 27362 | 0.000 |
Why?
|
| Middle Aged | 1 | 2016 | 223487 | 0.000 |
Why?
|